Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile?
ABSTRACT A two-step algorithm for the detection of Clostridium difficile by the use of C. Diff Quik Chek (TechLab, Blacksburg, VA) and a tissue culture cytotoxicity neutralization assay was found to be more sensitive than the widely used solid-phase enzyme immunoassay (EIA), the Premier toxin A and B EIA (Meridian Bioscience, Cincinnati, OH), and a newly developed, rapid single-test EIA for C. difficile toxins A and B (Tox A/B Quik Chek; TechLab).
- [show abstract] [hide abstract]
ABSTRACT: Diagnosis of Clostridium difficile-associated disease continues to be difficult for clinical microbiology laboratories. The aim of this study was to evaluate the performance of three enzyme immunoassays for detection of C. difficile toxins A and B: the recently marketed rapid enzyme immunoassay Ridascreen Clostridium difficile Toxin A/B (R-Biopharm, Darmstadt, Germany) and two established enzyme immunoassays, the C. difficile Tox A/B II Assay (TechLab, Blacksburg, VA, USA) and the ProSpecT C. difficile Toxin A/B Microplate Assay (Remel, Lenexa, KS, USA). Stool specimens (n = 383) from patients with a clinical diagnosis of antibiotic-associated diarrhea were examined by these three enzyme immunoassays and were additionally cultured for C. difficile on selective agar. Samples giving discordant enzyme immunoassay results underwent confirmatory testing by tissue culture cytotoxin B assay and by PCR for toxin A (tcdA) and toxin B (tcdB) genes from C. difficile. Using the criteria adopted for this study, 60 (15.7%) samples tested positive for toxins A and/or B. Sensitivity and specificity of the enzyme immunoassays were, respectively, 88.3 and 100% for the TechLab enzyme immunoassay, 91.7 and 100% for the R-Biopharm enzyme immunoassay, and 93.3 and 100% for the Remel enzyme immunoassay. The differences between these results are statistically not significant (p > 0.05). The results show that all three enzyme immunoassays are acceptable tests for the detection of C. difficile toxins A and B directly in fecal specimens or in toxigenic cultures.European Journal of Clinical Microbiology 02/2007; 26(2):115-9. · 3.02 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: Several kinds of laboratory techniques are available to detect Clostridium difficile toxin in fecal samples. Because questions have been raised about the reliability of immunoassays compared to the accepted standard, cytotoxicity assay, we studied three enzyme immunoassays (EIAs) and one rapid EIA, which demonstrated relatively good sensitivities and specificities compared to cytotoxicity assay.Journal of Clinical Microbiology 09/2007; 45(8):2737-9. · 4.07 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: Clostridium difficile is the principal pathogen associated with hospital-acquired acute diarrheal disease. We have evaluated the performances of six approaches for diagnosis of C. difficile-associated diarrhea (CDAD). Consecutive stool specimens (n = 200) from 133 patients were examined by cytotoxin assay, by culture of C. difficile on cycloserine-cefoxitin-fructose agar, and by toxin detection using four rapid immunoassay systems (Oxoid Toxin A test, ImmunoCard Toxin A test, TechLab Tox A/B II test, and Premier Toxins A&B test). A diagnosis of CDAD was established for 35 (27%) patients (representing 29% of specimens). The adjusted sensitivity and specificity of the methods were, respectively, 98 and 99% for the cytotoxin assay, 54 and 99% for ImmunoCard, 50 and 98% for Oxoid, 79 and 98% for TechLab, 80 and 98% for Premier, and 57 and 100% for culture. The TechLab and Premier assays are acceptable tests for diagnosis of CDAD but are not equivalent to the cytotoxin assay.Journal of Clinical Microbiology 09/2001; 39(8):2846-9. · 4.07 Impact Factor
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2008, p. 1523–1525
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Vol. 46, No. 4
Is a Two-Step Glutamate Dehyrogenase Antigen-Cytotoxicity
Neutralization Assay Algorithm Superior to the Premier
Toxin A and B Enzyme Immunoassay for Laboratory
Detection of Clostridium difficile??
Peter H. Gilligan*
Clinical Microbiology-Immunology Laboratories, University of North Carolina Hospitals, and Departments of
Microbiology-Immunology and Pathology-Laboratory Medicine, University of North Carolina School of
Medicine, Chapel Hill, North Carolina 27514
Received 31 October 2007/Returned for modification 11 December 2007/Accepted 25 January 2008
A two-step algorithm for the detection of Clostridium difficile by the use of C. Diff Quik Chek (TechLab,
Blacksburg, VA) and a tissue culture cytotoxicity neutralization assay was found to be more sensitive than the
widely used solid-phase enzyme immunoassay (EIA), the Premier toxin A and B EIA (Meridian Bioscience,
Cincinnati, OH), and a newly developed, rapid single-test EIA for C. difficile toxins A and B (Tox A/B Quik
The recent emergence of a highly virulent strain of Clostrid-
ium difficile, with its associated increased morbidity and in-
creased mortality, has placed a renewed emphasis on the lab-
oratory diagnosis of C. difficile disease (7, 10). For well over a
decade, first the Premier toxin A enzyme immunoassay (EIA)
and then the Premier toxin A and B EIA (A/B EIA; Meridian
Bioscience, Inc., Cincinnati, OH) were used to detect this toxin
(21). The latter is the most widely used test for the detection of
C. difficile toxins in the United States (4). Recent studies (11,
20) have shown that this assay has both excellent sensitivity
(?90%) and excellent specificity (?95%) compared to the
results of a tissue culture cytotoxicity neutralization (CTN)
assay, an assay frequently considered the “gold standard” for
the diagnosis of C. difficile disease (1, 9, 11, 12, 15, 18, 19, 21).
Other data suggest that the detection of toxigenic strains of C.
difficile is actually a more sensitive approach to the diagnosis of
C. difficile disease (5, 6, 13, 14), but culture is infrequently done
for diagnostic purposes in the United States because of its slow
turnaround time and the need for special isolation media and
technical expertise. In addition, the specificity of toxigenic cul-
ture for the diagnosis of C. difficile disease has also been ques-
tioned (1, 14).
Given the emergence of a highly virulent C. difficile strain in
the United States, a recent report by Ticehurst and colleagues
was a cause for concern (18). They showed that another widely
used EIA, the C. difficile Tox A/B II assay (TechLab, Blacks-
burg, VA), which has performance characteristics similar to
those of the A/B EIA (11, 12, 19), had a sensitivity of only 36%
for C. difficile detection when the results were compared to
those obtained by the use of a two-step algorithm in which
specimens were first tested for the presence of the glutamate
dehydrogenase (GDH) antigen by a solid-phase EIA (C. Diff
Chek-60; TechLab) and the positive results were confirmed by
the CTN assay. The test for the GDH antigen proved to be an
excellent screening test, with a sensitivity of ?95% and a neg-
ative predictive value of ?99% compared with the results of
the CTN assay (18). In practical terms, that meant that GDH-
negative specimens could be reported to be negative without
further testing. By using the CTN assay as a reference method,
it was found that the assay for the GDH antigen had a positive
predictive value of 53%, indicating that a confirmatory test was
required to detect specimens containing C. difficile toxins.
I applied the two-step algorithm approach using a modifi-
cation of the GDH antigen assay, which used a recently devel-
oped membrane-bound lateral flow device, C. Diff Quik Chek
(TechLab), and compared its performance characteristics to
those of the A/B EIA with a membrane-bound lateral flow
device (Tox A/B Quik Chek; TechLab) for the detection of
toxins A and B (the LF-A/B assay).
Three hundred sixty-eight clinical specimens submitted be-
tween April and June 2007 for the detection of C. difficile toxin
by the A/B EIA were studied. The inclusion criteria were as
follows: a clinician had to order the detection of C. difficile
toxin in a specimen, the specimen had to be less than 24 h old,
the specimen had to take the form of the specimen container,
and the specimen volume had to be sufficient to allow perfor-
mance of the four assays that were used in this study. All
specimens were stored at 4°C prior to assay. The A/B EIA, the
C. Diff Quik Chek assay (the GDH assay), the LF-A/B assay,
and the CTN assay with the TechLab C. difficile toxin B assay
were all done according to the manufacturer’s instructions,
with the exception that the results for specimens with optical
densities at 450/630 nm of 0.1 to 0.5 by the A/B EIA were
confirmed by the CTN assay. In-house data have shown that
only 30% of specimens with optical density values between 0.1
and 0.5 by the A/B EIA could be confirmed to be positive by
the CTN assay. Positive controls were run on each day of the
assay for all tests. In addition, a negative control was run for
the A/B EIA, while each of the GDH and LF-A/B assays has
* Mailing address: Clinical Microbiology-Immunology Laboratories,
UNC Hospitals, CB 7600, Chapel Hill, NC 27514. Phone: (919) 966-
6313. Fax: (919) 966-0486. E-mail: email@example.com.
?Published ahead of print on 6 February 2008.
an internal negative control. The individual performing the
GDH and the LF-A/B assays was blinded to the A/B EIA
For the purposes of comparisons of the algorithm with the
A/B EIA and the LF-A/B assays, specimens were assigned a
true-positive result by the two-step algorithm if they were both
GDH assay positive and CTN assay positive; they were as-
signed a true-negative result if they GDH assay negative or
GDH assay positive but CTN assay negative. These designa-
tions are based on the high sensitivity and the high negative
predictive value previously reported for this algorithm (18).
Confidence intervals were determined by the use of EP Eval-
uator software (David G. Rhoads Associates, Kennett Square,
PA). This study was approved by the Institutional Review
Board of the University of North Carolina.
Of the 368 specimens studied, 70 were positive and 298 were
negative by the GDH assay.
Of the 70 GDH assay-positive specimens, 37 were confirmed
to contain C. difficile toxin by the CTN assay. Only 22 of the 37
specimens confirmed to have positive results were positive by
the A/B EIA, resulting in an A/B EIA sensitivity of 59.5%. The
sensitivity was even lower for the LF-A/B assay (43%). The
positive predictive values, the negative predictive values, and
the specificities of the EIAs were all very good to excellent
(Table 1). Two specimens were found to be GDH assay neg-
ative but A/B EIA positive. Both specimens were negative by
the CTN assay. The results for five specimens found to be
positive by the LF-A/B assay could not be confirmed by the
CTN assay; two of the five specimens were also positive by the
The use of two-step diagnostic algorithms, in which an easily
performed and highly sensitive but less specific assay is used as
a screening test to eliminate specimens with negative results
and in which the results for specimens with positive results are
confirmed by a more specific but often more complex confir-
matory test, is a well-established diagnostic paradigm. Such
algorithms are widely used for the diagnosis of both syphilis
and human immunodeficiency virus infection (3). In the
present study, I wanted to learn if the two-step algorithm
described by Ticehurst et al. (18) would enhance the ability to
detect C. difficile toxin compared to the ability of the most
commonly used C. difficile toxin A and B EIA, the A/B EIA
(Meridian Bioscience). Although the differential was not as
dramatic as that reported by Ticehurst et al. (18), I found that
the two-step algorithm had an enhanced ability to detect C.
difficile toxin-positive specimens by 40% compared to the re-
sults of the A/B EIA. I also evaluated a novel lateral flow toxin
A and B EIA, the LF-A/B assay, but found it to be both less
sensitive and less specific than the A/B EIA.
What are some of the practical observations made during
this study? First, the LF-A/B assay had performance charac-
teristics very similar to those reported for the C. Diff Chek-60
assay (16, 18) in that it had a positive predictive value of only
53% but a sensitivity of 100% compared to tissue culture
results. Because the results for all negative specimens were not
confirmed by the CTN assay, the specificity and the negative
predictive value of this GDH assay cannot be stated with cer-
tainty. However, 293 of 298 of the GDH assay-negative spec-
imens were also negative by the two other immunoassays that
were studied, with the A/B EIA having been shown to be highly
specific and to have a high negative predictive value in several
studies (9, 11, 12, 15, 19). The seven GDH assay-negative
specimens that were positive by one of the two other EIAs
were found to be negative by the CTN assay. These data
suggest that the LF-A/B assay does have a very high negative
predictive value, a crucial characteristic of any screening test,
but because of the study design, this cannot be proven conclu-
Second, the GDH screening test is easily performed and the
results are easily interpreted. The test takes approximately 20
min to perform and is very simple, and the filters clogged for
less than 5 of 368 specimens tested. There was one failed run
during the study because the reagents were not added in the
proper order. This was determined by failure of the internal
control. I used positive controls on each day of use. Except for
the failed run, the positive control gave an appropriate reac-
tion each time, suggesting that positive controls need to be
tested only once per test lot. My laboratory can currently offer
this testing three times per day, and stat testing is also easily
accomplished. My laboratory can offer testing by the A/B EIA
only once a day, and stat testing is inconvenient and is rarely
Third, this approach is more expensive, and for an estimated
20% of specimens that require the CTN assay, the turnaround
time is delayed compared to the turnaround time for the EIA.
The material costs per specimen for the A/B EIA were approx-
TABLE 1. Performance characteristics of A/B EIA and the LF-A/B assay compared with those of a two-step algorithm using C. Diff Chek-60
and C. difficile toxin B assays
Test and result
No. of specimens with
the following two-step
Sensitivity (%)Specificity (%) NPVa(%)
99.4 (97.8–99.8) 95.6 91.7
43.2 (28.7–59.1)98.5 (96.5–99.4)93.9 76.2
aNPV, negative predictive value (predictive value of a negative test result).
bPPV, positive predictive value (predictive value of a positive test result).
cValues in parentheses are the 95% confidence limits, determined by the “score” method.
1524 NOTES J. CLIN. MICROBIOL.
imately $5.00, while the current per specimen cost for the
LF-A/B assay is $9.00. In addition, 20% of specimens require
the CTN assay, which has an approximate cost of $8.00. These
specimens require both centrifugation and filtration, which are
labor-intensive and which thus add further to the cost of this
algorithm. The overall material cost per specimen for the two-
step algorithm is $10.60. In order to provide the best possible
turnaround time, testing by the CTN assay must be offered 7
A major question concerning this study is the explanation for
the discrepancy between the high sensitivities (?90%) for the
A/B EIA reported recently (11, 20) and the comparatively
modest sensitivity found in this study (59.5%). It is possible
that there were systematic errors in the performance of this
assay during the study period. However, quality control failures
have been rare, and the lack of proficiency test failures since
the institution of this assay in my laboratory makes this type of
error less likely. Alternatively, there may have been a regional
shift in the antigenic nature of the toxin, resulting in the EIA
becoming less sensitive. I did notice that several of the GDH
assay- and CTN assay-positive but A/B EIA-negative speci-
mens were CTN positive only after 48 h of incubation, sug-
gesting the presence of low levels of toxin and perhaps explain-
ing the inability of the EIA to detect the toxin. However, a
similar number of EIA-negative specimens were GDH and
CTN assay positive at 24 h, suggesting that a low toxin level was
not the entire explanation for the relative insensitivity of the
The data presented here and by others (2, 6, 9, 16, 18)
indicate that GDH detection is the most sensitive and conve-
nient method by which C. difficile can be detected in stools. The
assay also has a high negative predictive value. Because of this
test’s modest positive predictive value of approximately 50%, a
rapid, convenient confirmatory test for GDH-positive speci-
mens is needed before this test is likely to gain wide acceptance
in clinical laboratories. The data presented here and by others
(18) indicate that two solid-phase EIAs, the C. difficile Tox A/B
II EIA (TechLab) and the A/B EIA (Meridian Bioscience), as
well as a single-test lateral flow immunochromatographic test,
the LF-A/B assay (TechLab), lack sufficient sensitivity com-
pared with the results of the CTN assay to be used as confir-
matory tests. For laboratories wishing to implement screening
for C. difficile by the GDH assay as part of a testing algorithm,
for now it is necessary to use either the CTN assay or toxigenic
culture (5, 6, 14) as a confirmatory test for GDH assay-positive
I thank Melissa B. Miller for critical assessment of the manuscript
and Gloria Crawford for statistical assistance.
I thank TechLab for providing the kits used in this study.
P.G. has received speaking fees from Remel, Lenexa, KS.
1. Bartlett, J. G. 2006. Narrative review: the new epidemic of Clostridium
difficile-associated enteric disease. Ann. Intern. Med. 145:758–764.
2. Barbut, F., V. Lalande, G. Daprey, P. Cohen, N. Marle, B. Burghoffer, and
J. C. Petit. 2000. Usefulness of simultaneous detection of toxin A and
glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated
diseases. Eur. J. Clin. Microbiol. Infect. Dis. 19:481–484.
3. Centers for Disease Control and Prevention. 2006. Sexually transmitted
diseases treatment guidelines, 2006. MMWR Recommend. Rep. 55:1–94.
4. College of American Pathology. 2006. D-B bacteriology: sample D-13, p.9.
College of American Pathology, Northfield, IL.
5. Delmee, M., J. Van Broeck, A. Simon, M. Janssens, and V. Avesani. 2005.
Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for
culture. J. Med. Microbiol. 54:187–191.
6. Fenner, L., A. F. Widmer, G. Goy, S. Rudin, and R. Frei. 2008. Reliable
diagnostic algorithm for detection of Clostridium difficile. J. Clin. Microbiol.
7. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud,
A. M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard,
S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. Rene, Y. Monczak, and A.
Dascal. 2005. A predominantly clonal multi-institutional outbreak of Clos-
tridium difficile-associated diarrhea with high morbidity and mortality.
N. Engl. J. Med. 353:2442–2449.
8. Reference deleted.
9. Massey, V., D. B. Gregson, A. H. Chagla, M. Storey, M. A. John, and Z.
Hussain. 2003. Clinical usefulness of components of the Triage immunoas-
say, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture
assay for the diagnosis of Clostridium difficile diarrhea. Am. J. Clin. Pathol.
10. McDonald, L. C., G. E. Killgore, A. Thompson, R. C. Owens, Jr., S. V.
Kazakova, S. P. Sambol, S. Johnson, and D. N. Gerding. 2005. An epidemic,
toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433–
11. Musher, D. M., A. Manhas, P. Jain, F. Nuila, A. Waqar, N. Logan, B.
Marino, and E. A. Graviss. 2007. Detection of Clostridium difficile toxin:
comparison of enzyme immunoassay results with results obtained by cyto-
toxicity assay. J. Clin. Microbiol. 45:2737–2739.
12. O’Connor, D., P. Hynes, M. Cormican, E. Collins, G. Corbett-Feeney, and
M. Cassidy. 2001. Evaluation of methods for detection of toxins in specimens
of feces submitted for diagnosis of Clostridium difficile-associated diarrhea.
J. Clin. Microbiol. 39:2846–2849.
13. Peterson, L. R., R. U. Manson, S. M. Paule, D. M. Hacek, A. Robicsek, R. B.
Thomson, Jr., and K. L. Kaul. 2007. Detection of toxigenic Clostridium
difficile in stool samples by real-time polymerase chain reaction for the
diagnosis of C. difficile-associated diarrhea. Clin. Infect. Dis. 45:1152–1160.
14. Reller, M. E., C. A. Lema, T. M. Perl, M. Cai, T. L. Ross, K. A. Speck, and
K. C. Carroll. 2007. Yield of stool culture with isolate toxin testing versus a
two-step algorithm including stool toxin testing for detection of toxigenic
Clostridium difficile. J. Clin. Microbiol. 45:3601–3605.
15. Russmann, H., K. Panthel, R. C. Bader, C. Schmitt, and R. Schaumann.
2007. Evaluation of three rapid assays for detection of Clostridium difficile
toxin A and toxin B in stool specimens. Eur. J. Clin. Microbiol. Infect. Dis.
16. Snell, H., M. Ramos, S. Longo, M. John, and Z. Hussain. 2004. Performance
of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combi-
nation with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel
immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-
associated diarrhea. J. Clin. Microbiol. 42:4863–4865.
17. Reference deleted.
18. Ticehurst, J. R., D. Z. Aird, L. M. Dam, A. P. Borek, J. T. Hargrove, and
K. C. Carroll. 2006. Effective detection of toxigenic Clostridium difficile by a
two-step algorithm including tests for antigen and cytotoxin. J. Clin. Micro-
19. Turgeon, D. K., T. J. Novicki, J. Quick, L. Carlson, P. Miller, B. Ulness, A.
Cent, R. Ashley, A. Larson, M. Coyle, A. P. Limaye, B. T. Cookson, and T. R.
Fritsche. 2003. Six rapid tests for direct detection of Clostridium difficile and
its toxins in fecal samples compared with the fibroblast cytotoxicity assay.
J. Clin. Microbiol. 41:667–670.
20. van den Berg, R. J., N. Vaessen, H. P. Endtz, T. Schulin, E. R. van der Vorm,
and E. J. Kuijper. 2007. Evaluation of real-time PCR and conventional
diagnostic methods for the detection of Clostridium difficile-associated diar-
rhoea in a prospective multicentre study. J. Med. Microbiol. 56:36–42.
21. Whittier, S., D. S. Shapiro, W. F. Kelly, T. P. Walden, K. J. Wait, L. T.
McMillon, and P. H. Gilligan. 1993. Evaluation of four commercially avail-
able enzyme immunoassays for laboratory diagnosis of Clostridium difficile-
associated diseases. J. Clin. Microbiol. 31:2861–2865.
VOL. 46, 2008NOTES1525